Ciltacabtagene autoleucel (Carvykti) — Clinical FAQs

Question 1

What is Ciltacabtagene autoleucel FDA-approved to treat?

Accepted Answer

Ciltacabtagene autoleucel is FDA-approved for the following oncology indications: 1. Relapsed or refractory multiple myeloma in adults who have received at least 4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (FDA approved February 28, 2022; based on CARTITUDE-1) 2. Relapsed or refractory multiple myeloma in adults who have received 1–3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent and are refractory to lenalidomide (FDA expanded approval April 2024; based on CARTITUDE-4).

Question 2

How does Ciltacabtagene autoleucel work (mechanism of action)?

Accepted Answer

Ciltacabtagene autoleucel (cilta-cel) is an autologous BCMA-directed CAR-T cell therapy featuring a unique dual-VHH (nanobody) design with two camelid-derived single-domain anti-BCMA antibody fragments arranged in tandem on the CAR construct, providing bivalent BCMA binding with potentially enhanced avidity. The CAR also incorporates 4-1BB and CD3ζ signaling domains. BCMA (B-cell maturation antigen, TNFRSF17) is highly expressed on malignant plasma cells and late-stage B cells but has limited expression on most normal tissues, providing a therapeutic window in multiple myeloma. Following infusion into lymphodepleted patients, cilta-cel cells expand, home to BCMA-expressing myeloma cells, and mediate targeted cytotoxicity. The dual-nanobody architecture may contribute to high depth of response and the distinctive prolonged CRS and delayed neurotoxicity profile observed in clinical trials.

Question 3

How is Ciltacabtagene autoleucel administered?

Accepted Answer

Ciltacabtagene autoleucel is administered Intravenous (IV). Single IV infusion at a REMS-certified center.

Question 4

What are the most common side effects of Ciltacabtagene autoleucel?

Accepted Answer

The most commonly reported side effects of Ciltacabtagene autoleucel (≥10% incidence) include: CRS (any grade ~95%), Pyrexia, Hypotension, Tachycardia, Musculoskeletal pain and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Ciltacabtagene autoleucel have a black box warning?

Accepted Answer

Yes. Ciltacabtagene autoleucel carries FDA black box warning(s) regarding: 1. Cytokine release syndrome (CRS): may be prolonged (median onset Day 7); manage per ASTCT grading criteria with tocilizumab ± corticosteroids 2. Immune effector cell-associated neurotoxicity syndrome (ICANS): includes a distinctive delayed movement and neurocognitive symptoms (MNS) unique to cilta-cel, observed weeks to months post-infusion 3. Prolonged and severe cytopenias 4. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) 5. Available only through the CARVYKTI REMS Program

Question 6

Is Ciltacabtagene autoleucel safe during pregnancy?

Accepted Answer

Ciltacabtagene autoleucel pregnancy safety: No human data; potential for fetal harm. Patients of reproductive potential should use effective contraception for at least 6 months after infusion. Unknown breast milk excretion; breastfeeding not recommended.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

ciltacabtagene autoleucel — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms